全脑放疗追加辐射推量可能改善小细胞肺癌脑转移患者的生存
该回顾性分析纳入2008年1月至2015年12月接受全脑放疗联合推量(33例)或单纯全脑放疗(49例)的82例小细胞肺癌脑转移患者,所有患者初诊时为局限期且检出脑转移前无颅外转移。全脑放疗联合推量组中位总生存为13.4个月,单纯全脑放疗组为8.5个月(p=0.004)。作者认为全脑放疗联合推量可能延长此类患者生存,对部分小细胞肺癌脑转移患者应考虑脑放疗剂量递增策略。
要点
- 82例小细胞肺癌脑转移患者中,全脑放疗联合推量组中位总生存13.4个月,单纯全脑放疗组8.5个月(p=0.004)。
- 在1至3个脑转移灶患者中,联合推量组中位总生存13.4个月,单纯全脑放疗组9.6个月(p=0.022)。
- 基线时单纯全脑放疗组脑转移灶超过3个的比例显著高于联合推量组(p=0.0001)。
核心结论
- 与单纯全脑放疗相比,全脑放疗联合辐射推量可能延长小细胞肺癌脑转移患者的生存。
- 作者认为,对部分小细胞肺癌脑转移患者应考虑脑放疗剂量递增策略。
研究设计与样本
- 回顾性分析2008年1月至2015年12月收治的82例小细胞肺癌脑转移患者,其中全脑放疗联合推量组33例,单纯全脑放疗组49例。
- 所有患者初诊时为局限期小细胞肺癌,检出脑转移前均无颅外转移,主要终点为总生存。
主要发现
- 全部患者中位总生存为9.6个月,6个月、12个月和24个月总生存率分别为69.1%、42.2%和12.8%。
- 基线时单纯全脑放疗组脑转移灶超过3个的比例显著高于全脑放疗联合推量组(p=0.0001)。
- 全脑放疗联合推量组中位总生存为13.4个月,单纯全脑放疗组为8.5个月(p=0.004)。
- 在1至3个脑转移灶患者中,全脑放疗联合推量组中位总生存为13.4个月,单纯全脑放疗组为9.6个月(p=0.022)。
临床怎么用
- 作者认为,对部分小细胞肺癌脑转移患者应考虑脑放疗剂量递增策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of the dose escalation strategy in brain radiotherapy for small cell lung cancer (SCLC) patients with brain metastases (BMs) has not been identified. This study aims to determine whether an additional radiation boost to whole brain radiation therapy (WBRT) has beneficial effects on overall survival (OS) compared with WBRT-alone. METHODS: A total of 82 SCLC patients who were found to have BMs treated with WBRT plus a radiation boost (n = 33) or WBRT-alone (n = 49) from January 2008 to December 2015 were retrospectively analyzed. All patients were limited-stage (LS) SCLC at the time of the initial diagnosis, and none of them had extracranial metastases prior to detection of BMs. The primary end point was OS. RESULTS: The median OS for all of the patients was 9.6 months and the 6-, 12- and 24-months OS rates were 69.1, 42.2 and 12.8%, respectively. At baseline, the proportion of more than 3 BMs was significantly higher in the WBRT group than in the WBRT plus boost group (p = 0.0001). WBRT plus a radiation boost was significantly associated with improved OS in these patients when compared with WBRT-alone (13.4 vs. 8.5 months; p = 0.004). Further, the survival benefit still remained significant in WBRT plus boost group among patients with 1 to 3 BMs (13.4 vs. 9.6 months; p = 0.022). CONCLUSION: Compared with WBRT-alone, the use of WBRT plus a radiation boost may prolong survival in SCLC patients with BMs. The dose escalation strategy in brain radiotherapy for selected BMs patients with SCLC should be considered.
引用
- Sun H, Xu L, Wang Y, et al. Additional radiation boost to whole brain radiation therapy may improve the survival of patients with brain metastases in small cell lung cancer. Radiat Oncol. 2018. PMID: 30563554. doi:10.1186/s13014-018-1198-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。